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BACKGROUND: Thromboembolic events are a major complication in ovarian cancer patients. Tissue factor (TF) is frequently
overexpressed in ovarian cancer tissue and correlates with intravascular thrombosis. TF binds to coagulation factor VII (fVII), changing
it to its active form, fVIIa. This leads to activation of the extrinsic coagulation cascade. fVII is produced by the liver and believed to be
supplied from blood plasma at the site of coagulation. However, we recently showed that ovarian cancer cells express fVII transcripts
under normoxia and that this transcription is inducible under hypoxia. These findings led us to hypothesise that ovarian cancer cells
are intrinsically associated with TF-fVIIa coagulation activity, which could result in thrombosis.
METHODS: In this study, we examined whether ectopically expressed fVII could cause thrombosis by means of immunohistochemistry,
RT–PCR, western blotting and flow cytometry.
RESULTS: Ectopic fVII expression occurs frequently in ovarian cancers, particularly in clear cell carcinoma. We further showed that
ovarian cancer cells express TF-fVIIa on the cell surface under normoxia and that this procoagulant activity is enhanced by hypoxic
stimuli. Moreover, we showed that ovarian cancer cells secrete microparticles (MPs) with TF-fVIIa activity. Production of this
procoagulant secretion is enhanced under hypoxia.
CONCLUSION: These results raise the possibility that cancer cell-derived TF-fVIIa could cause thrombotic events in ovarian cancer
patients.
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Venous thromboembolism (VTE) is a common complication in
cancer patients and a significant cause of morbidity and mortality
(Chew et al, 2007; Varki, 2007). The risk of VTE is highest for
cancers of the ovary, pancreas and liver (Iodice et al, 2008). In fact,
ovarian cancer patients closely associate with intravascular
thrombosis (Tateo et al, 2005; Satoh et al, 2007), and the
development of VTE within 2 years is a strong predictor of death
due to this cancer (Rodriguez et al, 2007). Activation of platelets
and elevation of plasma tissue factor (TF) levels (Han et al, 2006;
Tesselaar et al, 2007) are candidate determinants for the
development of thrombosis in cancer patients.
Numerous studies have suggested that TF may have an
important function in thrombosis in cancer patients. TF primarily
presents on the cell surface as a transmembrane protein and
functions as a cellular receptor for coagulation factor VII (fVII)
circulating in the blood (Furie and Furie, 1988). By binding with
TF, fVII is changed to its active form, fVIIa, and subsequently
triggers the extrinsic coagulation cascade by activating factor X
(Furie and Furie, 1988). Overexpression of TF correlates with a
high incidence of VTE in pancreatic (Khorana et al, 2007) and
ovarian (Uno et al, 2007) cancer patients. We have also reported
that TF is constitutively expressed in many tumour cell lines
(Koizume et al, 2006). Functionally active TF also circulates in the
blood as a component of cell-derived microparticles (MPs)
produced by platelets, cells with a monocyte/macrophage lineage
(Lopez et al, 2005) and cancer cells (Amin et al, 2008). It is likely
that this circulating TF may contribute to the development of
thrombosis.
Hypoxia is a condition closely associated with cancer (Dewhirst
et al, 2008), including ovarian cancer (Kim et al, 2006). The gene
encoding TF is activated under hypoxia by a transcription factor,
Egr-1, found in glioblastoma (Rong et al, 2005), melanoma, breast,
lung (Amirkhosravi et al, 1998) and cervical cancer cells (Denko
et al, 2000). To date, hypoxic induction of TF in ovarian cancer
cells has not been reported.
In an earlier study, we showed that fVII, primarily synthesised in
the liver, was constitutively produced in various non-hepatic
cancer cells including ovarian cancer cells (Koizume et al, 2006).
Furthermore, fVII transcription was inducible under hypoxic
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sconditions by the hypoxia-inducible factor-2a (HIF-2a)-dependent
pathway in ovarian cancer cells (Koizume et al, 2006). Thus, we
surmised that fVII and TF induced by hypoxia in ovarian cancer
cells, and not fVII derived from circulating blood, may be involved
in thrombotic events in ovarian cancer patients.
The aim of this study was to examine the possibility that ovarian
cancer tissue could intrinsically produce the TF-fVIIa complex
independently of fVII supplied from blood plasma, and thus
increase the risk of thrombosis. To this end, we investigated the
expression of TF and fVII and the secretion of plasma membrane-
derived MPs in ovarian cancer cells under both normoxia and
hypoxia.
MATERIALS AND METHODS
Cell lines and cell culture
Ovarian cancer cell lines including four clear cell carcinoma
(OVSAYO, OVISE, OVMANA, and OVTOKO); two serous adeno-
carcinoma (OVSAHO and OVKATE); one mucinous adenocarci-
noma (MCAS); one endometrioid adenocarcinoma (TOV112D)
and three undifferentiated carcinoma (KURAMOCHI, NIH:OV-
CAR-3, and TYK-nu) cell lines were used in this study. TOV112D
and NIH:OVCAR-3 were obtained from the American Type
Culture Collection (Manassas, VA, USA). Other cell lines were
described earlier (Koizume et al, 2006). All cell lines were cultured
in RPMI-1640 medium supplemented with 10% foetal bovine
serum (Moregate, Brisbane, Australia) at 371C in a humidified
atmosphere under 5% CO2.
Real-time RT–PCR analysis of FVII and TF gene
expression
Cancer cells were harvested at the exponential growth phase. Cells
(2 10
6 cells) were seeded on to a 100mm-diameter dish and
cultured for 16h. Cells were further cultured under normoxia or
hypoxia (1% O2) as described earlier (Koizume et al, 2006). Total
RNA isolated from cancer cells was subjected to real-time RT–PCR
analysis as described earlier (Koizume et al, 2006). The PCR
primers used for TF expression were 50-TAACCGGAAGAGTACA
GACAGC-30 and 50-CACTCCTGCCTTTCTACACTTG-30. The
hybridisation probes used were 50-ATCATTGGAGCTGTGGTA
TTTGTGG-FITC-30 and 50-LCRed640-CATCATCCTTGTCATCATC
CTGGC-30. Expression of porphobilinogen deaminase was ana-
lysed as described earlier (Koizume et al, 2006) to normalise data.
Isolation of MPs
To isolate cell-derived MPs, conditioned media were filtered
through a 5mm-pore membrane, then ultracentrifuged at 100000g
for 90min at 101C according to a published procedure (Davila
et al, 2008). To isolate MPs secreted under serum-free condition,
cultured cells were washed twice with 5ml of PBS, then cultured in
serum-free media for 3h. Media were then replaced with new
serum-free media and further cultured under normoxia or hypoxia
for 24h. Obtained conditioned media were processed as described
above.
fXa generation assay
The activated factor X (fXa) generation assay was performed as
described earlier (Koizume et al, 2006) with a slight modification
of seeded cell numbers (1 10
5cells per well of a 24-well plate).
Briefly, conditioned media were collected and filtered through a
5mm-pore filter (Millex-SV, Millipore, Billerica, MA, USA) to
remove cell debris. Six microlitres of 250mM CaCl2 (final
concentration was 5mM) and 175nM fX were added to 294mlo f
the filtered conditioned medium. After incubation at 371C for 4
and 2h for cells and conditioned media, respectively, a 20ml
aliquot was removed and used for the analysis. In addition, MPs
were resuspended in reaction buffer and subjected to fXa
generation analysis.
The tilt tube plasma clotting assay
Tilt tube plasma clotting assay was performed as described earlier
(Rong et al, 2005) with slight modifications. The filtered
conditioned medium (200ml) was mixed with 200ml of citrated
normal human plasma (George King Bio-Medical, Inc., Overland
Park, KS, USA), and then 200mlo f2 5m M CaCl2 was added to the
tube to initiate the semisolid gel formation. The times required for
clot formation were recorded to evaluate procoagulant activity.
Flow cytometry
MPs of 15ml were diluted with 85ml of binding buffer (0.01M
Hepes [pH 7.4], 140mM NaCl and 2.5mM CaCl2), and then each
sample was incubated with 5ml of FITC annexin V (BD-
Pharmingen, San Jose, CA, USA) and/or 20ml of PE-conjugated
monoclonal anti-TF antibody (BD-Pharmingen) for 15min at
room temperature. To detect fVII on the MPs, diluted MPs were
incubated with 10ml of monoclonal anti-fVII antibody (F8146,
Sigma, Saint Louis, MO, USA) labelled with FITC using DyLight
Antibody Labeling Kits (Thermo Scientific, Rockford, IL, USA).
We used unlabelled samples, an isotype-matched mouse IgG-PE or
mouse IgG-FITC (BD-Pharmingen) as controls. MPs were analysed
by size, using 1mm calibration microspheres (Molecular Probes
Inc., Eugene, OR, USA), and fluorescence using a Coulter Epics
Altra flow cytometer (Beckman Coulter Inc., San Diego, CA, USA).
Western blotting
Immunoblotting was performed using whole-cell lysates of cancer
cells. The antibodies used were the anti-TF monoclonal antibody
(TF9 10H10), the anti-Egr-1 (sc-110, Santa Cruz Biotechnology
Inc., CA, USA), the anti-Sp-1 (sc-59, Santa Cruz) and the anti-
b-actin (A5441, Sigma) antibodies. Detection of antibodies was
achieved using enhanced chemiluminescence reagents (Thermo
Scientific).
Immunohistochemistry
The institutional review board at Yokohama City University
approved this study. Surgically removed ovarian carcinomas were
obtained from the Department of Obstetrics and Gynecology,
Yokohama City University Hospital. Routinely processed forma-
lin-fixed paraffin-embedded specimens were sectioned and stained
with antibodies for TF (TF CPT at 7.6mgml
 1) and fVII (fVII
R0882 at 10mgml
 1). Immunoreactivity was visualised by the
peroxidase-labelled amino acid polymer method with Histofine
simple stain MAX-PO(R) (Nichirei Co., Tokyo, Japan) and by
the avidin–biotin–peroxidase complex method (LSABþ, Dako-
Cytomation Co., Tokyo, Japan) according to the manufacturer’s
instructions. Sections were counterstained with haematoxylin.
Data were obtained using the modified German immuno-
reactive score (Krajewska et al, 1996). Briefly, immunostaining
intensity was rated using four ranks ranging from zero (none) to
three (intense). The numbers of immunoreactive cancer cells
were also estimated in four grades as zero (none), one (1–10%
per cancer cells), two (10–50%) and three (50%o). Two
representative areas were evaluated for each case, and the sum of
the scores was used for the score of that case. Two independent
examiners scored each case and the average value was used for
analyses.
Ovarian cancer self-production of tissue factor-factor VII
N Yokota et al
2024
British Journal of Cancer (2009) 101(12), 2023–2029 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sRESULTS
Ectopic expression of fVII in human epithelial ovarian
carcinoma
We first examined the expression of TF and fVII in ovarian cancer
tissues using 20 surgically removed specimens. The specimens
consisted of five serous, three mucinous and three endometrioid
adenocarcinomas, as well as seven clear cell carcinomas and one
normal premenopausal ovary with normal ovarian surface
epithelium (OSE) (Figure 1). Immunohistochemical analysis
revealed a strong TF expression in mucinous and endometrioid
adenocarcinomas, in addition to clear cell carcinomas as reported
earlier (Uno et al, 2007) (Figure 1A and B). TF was less strongly
expressed in serous adenocarcinomas. TF was not detected in OSE
(Figure 1A). Immunohistochemistry also revealed that fVII was
expressed in all ovarian cancer specimens examined, particularly
in clear cell carcinomas (Figure 1A and B).
Hypoxia induction of fVII and TF transcription in ovarian
cancer cells of various histological types
Under normoxia, we showed earlier that OVSAYO, OVISE,
OVSAHO and OVTAKE cells weakly expressed fVII mRNA and
that KURAMOCHI strongly expressed fVII mRNA. In the past,
hypoxic FVII gene induction has been examined in detail only
for OVSAYO cells (Koizume et al, 2006). Thus, in this study, we
examined whether the FVII gene was inducible using hypoxia in
additional ovarian cancer cell lines. We first used 500mM CoCl2 to
mimic hypoxic conditions, as this approach has been shown to
stimulate higher levels of HIFs in cancer cells, as compared with
real hypoxic (1% O2) conditions (Koizume et al, 2008). Real-time
RT–PCR analysis revealed that fVII transcription was clearly
inducible by CoCl2 in several cell lines (Figure 2A). Constitutively
expressed TF mRNA in ovarian cancer cells (Koizume et al, 2006)
was also found to be upregulated in some cells after CoCl2
treatment (Figure 2A).
We next carried out a study under real hypoxic conditions (1%
O2 for 24h) for fVII and TF transcriptional activation in clear cell
carcinoma cell lines OVSAYO and OVISE. Immunohistochemistry
and RT–PCR analyses revealed that this histological subtype could
highly express fVII and TF transcripts. Quantitative RT–PCR
analysis revealed that real hypoxia also induced fVII and TF
transcriptions (Figure 2B). TF mRNA levels were quite high under
normoxia and hypoxia, compared with those of ectopically
expressed fVII (Koizume et al, 2006), enabling us to identify TF
protein by western blotting (Figure 2C).
Transcription factor Egr-1 is known to be upregulated and has
a dominant function over Sp1 for TF gene induction under
hypoxia (Yan et al, 1998; Rong et al, 2006). As a consequence, we
additionally tested the expression of Egr-1 in ovarian cancer cell
lines. Western blotting revealed that Egr-1 expression was
enhanced under CoCl2 or 1% O2 conditions. In contrast,
expression of Sp1, which is responsible for basal TF transcription,
was unchanged in these cell lines (Figure 2D).
Hypoxia-induced procoagulant activity in ovarian cancer
cells
The TF-fVIIa complex cleaves fX to generate fXa, further activating
the extrinsic coagulation cascade. To evaluate whether TF and fVII
expressions in ovarian cancer cells caused the procoagulant
reaction, we performed the fXa generation assay. OVSAYO and
OVISE cells were cultured under normoxic, mimicked hypoxic
(500mM CoCl2) and real hypoxic (1% O2) conditions. They were
then tested for coagulation activity. We found that the fXa-
generating activity of OVSAYO cells (10.6pM per min) and OVISE
cells (13.7pM per min) was significantly higher than that of the
cell-free control experiment (Figure 2E), suggesting that OVSAYO
and OVISE cells expressed procoagulant activity on their surface
under normoxia. As expected, both real hypoxic and CoCl2-
induced conditions enhanced procoagulant activity on OVSAYO
and OVISE cells (Figure 2E). Further, the addition of anti-TF (5G9)
antibody markedly reduced the procoagulant activity, although
normal IgG failed to inhibit it (Figure 2E). This suggested that the
TF-fVIIa complex was responsible for the observed procoagulant
activity.
TF-fVIIa activity in ovarian cancer cells under normoxia
and hypoxia
Increased plasma TF levels have been reported to correlate with
thrombosis in several cancer patients. In this context, we showed
that ovarian cancer cells could intrinsically express TF-fVIIa
activity on their surface. Thus, we next investigated whether
ovarian cancer cells could secrete the TF-fVIIa complex without
fVII derived from blood plasma. OVSAYO and OVISE cells were
cultured under normoxia or 1% O2, and conditioned media were
subsequently collected. These conditioned media were then mixed
with citrated human normal plasma supplemented with CaCl2, and
gently rocked for the tilt tube assay. The clotting time achieved
using conditioned media, prepared from cells cultured under
normoxia, was markedly reduced as compared with experiments
using cell-free medium (Figure 3). As expected, experiments with
conditioned media, prepared from cells cultured under hypoxia,
revealed that clotting times were further shortened (Figure 3). The
coagulation reactions were completely blocked by 5G9 antibody
treatment (data not shown). These results suggested that ovarian
cancer cells could secrete functional TF.
We further performed the same clotting assay using fVII-
deficient plasma. As expected, clotting times were generally longer
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Figure 1 Immunohistochemical analysis of TF and fVII expressions in
ovarian cancer tissues. (A) Expression level of TF and fVII in ovarian cancer
and normal ovarian surface epithelium (OSE) of a pre-menopausal ovary.
Ovarian cancer tissues from serous, mucinous, endometrioid adenocarci-
nomas, clear cell carcinoma and OSE were stained with TF or fVII antibody.
Expression levels were rated using the modified German immunoreactive
score. *P¼0.002, **P¼0.039 (Student’s t-test). (B) A representative
example of immunohistochemical detection of TF and fVII in an ovarian
clear cell carcinoma tissue that was scored as 11.5 and 11.0 for TF and fVII,
respectively.
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sthan those recorded in experiments using normal fVII-containing
plasma (Figure 3). However, plasma clotting was considerably
enhanced under hypoxia in the absence of fVII (Figure 3). As
expected, positive control experiments using fVII-overexpressing
OVSAYO cells (Koizume et al, 2006) showed further reduced
clotting times, in comparison with experiments involving empty
vector-transfected cells (Figure 3). This suggested that ectopically
synthesised fVII is secreted as a functional procoagulant in ovarian
cancer cells.
Secretion of MPs with TF-fVIIa activity by ovarian cancer
cells
TF has been shown to circulate in the blood as a component of cell-
derived MPs released as fragments of plasma membrane. Secretion
of TF-positive MPs has been found to be increased and associated
with the activation of the haemostatic system in several cancer
patients (Hron et al, 2007; Davila et al, 2008). Following up on this
finding, we next investigated whether TF-fVIIa secreted from
ovarian cancer cells was associated with the activity of MPs.
Conditioned media from ovarian cancer cell culture under 1% O2
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Figure 2 Real-time RT–PCR analysis of TF and fVII expressions in ovarian cancer cells. (A) Relative fVII and TF mRNA levels in ovarian cancer cells
stimulated with 500mM CoCl2 for 4h. fVII transcription in OVSAYO and OVSAHO cells was reported earlier (Koizume et al, 2006) but was re-examined for
comparison. *Po0.05, ND; not detected. (B) Relative increase of fVII and TF transcripts in OVSAYO and OVISE cells cultured under 1% O2 for 24h
compared with those cultured under normoxia (*Po0.001, **P¼0.023, ***P¼0.016, ****P¼0.003). Columns for fVII and TF mRNA levels, mean
(n¼3); Bars, s.d. Data were statistically analysed using Student’s t-test. (C) Western blotting analysis of TF levels in ovarian cancer cells. N and H are
indicative of normoxia and hypoxia, respectively. (D) Western blotting analysis of Egr-1 and Sp1 expressions in ovarian cancer cells cultured under normoxia,
hypoxia (1% O2 for 16h) or hypoxia mimic (500mM CoCl2 for 4h) conditions. (E) Induction of procoagulant activity on the cell surface of ovarian cancer
cells under CoCl2 or hypoxic conditions. Ovarian cancer cells were cultured under 500mM CoCl2 for 11h or under 1% O2 for 16h, and then subjected to
fXa generation assay. Columns for clotting time, mean (n¼3); Bars, s.d. *P¼0.001, **P¼0.002, ***Po0.001, ****P¼0.012.
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Figure 3 Secretion of procoagulant activity by ovarian cancer cells.
Ovarian cancer cells were cultured under normoxia or 1% O2 for 24h, and
then conditioned media were subjected to the plasma clotting assay using
normal or fVII-deficient human plasma. FVII-containing cells and empty cells
were indicative of stably fVII cDNA-transfected cells and stably transfected
empty vector cells, respectively. Columns for clotting time, mean (n¼3);
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swere ultracentrifuged. Coagulation activity was then assessed for
both supernatant and precipitate fractions. The fXa generation
assay revealed that TF-fVIIa activity was predominantly enhanced
in the precipitate that included MPs (Figure 4A). As expected,
procoagulant activity was blocked by anti-human TF antibody
treatment (Figure 4A).
We performed flow cytometry to further examine whether the
activity of TF-fVIIa secreted by ovarian cancer cells was associated
with MPs. The analysis revealed that most of the particles (B90%)
present in the precipitate from the serum-free conditioned media
bind to annexin V. They were smaller than 1mm in size (Figure 4B
and C), thus satisfying the criteria for being MPs. MPs were also
found to be TF positive by FACS analysis (Figure 4Da). The
number of TF-positive MPs secreted into serum-free conditioned
media from OVSAYO cells, maintained under 1% O2, increased by
B1.3 times compared with total MPs, including microvesicles not
associated with TF (Figure 4Db). Flow cytometry with anti-human
fVII antibody showed that the TF-positive MP fraction prepared
from serum-free culture media was also fVII positive (Figure 4Ea
and Eb), eliminating the possibility that pre-existing trace fVII in
bovine serum was responsible for binding TF-positive MPs. The
number of fVII-positive MPs was increased under hypoxia relative
to the number of TF-positive MPs (Figure 4E). These results
suggested that ovarian cancer cells secreted TF-fVIIa-positive MPs.
DISCUSSION
In this study, we showed that not only TF but also fVII proteins
were localised to cancer cells in surgically removed ovarian cancer
tissue specimens. This was especially true in the case of clear cell
carcinomas. Unlike TF expressions, the fVII expression evaluated
by immunohistochemistry was generally weak, except for clear cell
carcinomas, and was comparable with that of a normal ovarian
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Figure 4 Secretion of MPs with TF-fVIIa activity by ovarian cancer cells. (A) fXa generation activity of the supernatant and precipitate fraction of
conditioned media prepared from OVSAYO and OVISE cells cultured under 1% O2. Procoagulant activity predominantly presented in the precipitate
fraction and this activity was completely blocked by anti-TF (5G9) antibody treatment. *Po0.001, **P¼0.001. (B) Flow cytometry analysis of precipitate
fraction immunostained with PE-coupled anti-TF antibody and/or FITC-coupled annexin V showed that precipitate fraction prepared from conditioned
media of OVSAYO cells was annexin-V positive. (C) The extracellular procoagulants analysed by flow cytometry. The grey peak corresponds to the 1-mm
calibration microspheres. The white peak corresponds to the precipitate fraction prepared from conditioned media of OVSAYO cells. (D) Flow cytometry
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figure denote amounts of fVII-positive fractions relative to total MPs.
Ovarian cancer self-production of tissue factor-factor VII
N Yokota et al
2027
British Journal of Cancer (2009) 101(12), 2023–2029 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
stissue. fVII that came from blood plasma perhaps cross-reacts in
histochemical analysis. Furthermore, we found that hypoxic
conditions induced the expression of the FVII gene, together with
the TF gene, in various types of ovarian cancer cells. We showed
that slight TF-fVIIa activity on the surface of ovarian cancer cells
under normoxia was enhanced under hypoxic conditions. We
further showed that TF-fVIIa activity was not only localised on the
cancer cell surface, but was also secreted into culture media as a
component of MPs. Hypoxia was found to accelerate this process.
The TF-fVIIa complex on the ovarian cancer cell surface may
trigger the extrinsic coagulation cascade within or around ovarian
cancer tissue. TF-fVIIa on the cell surface is also known to
transduce various kinds of signals within cells. Both the products
of the coagulation cascade and transduced signals in cells have
important functions in cancer biology, such as cell invasion and
migration, angiogenesis and cell survival through intracellular
signalling mechanisms (Ruf, 2007). We showed earlier that ectopic
synthesis of fVII in OVSAYO cells, followed by TF-fVIIa formation
on the cell surface, markedly enhanced cell motility and invasion
(Koizume et al, 2006). Ovarian cancer is highly metastatic and
tumour cell migration from the primary site to the peritoneal
cavity is the critical process of ovarian cancer spread. Given that
cells in primary ovarian cancer tissue and ovarian cancer cells in
ascites undergo hypoxic stress (Kim et al, 2006), self-production of
TF-fVIIa on the cell surface may contribute to metastasis of
ovarian cancer.
In addition to cell surface localisation, TF could circulate in the
blood even under normal conditions. TF is found in the blood as
an alternatively spliced soluble form without the transmembrane
domain or as a component of cell-derived MPs. Most of the TF-
derived procoagulant activity is associated with MPs (Yu and Rak,
2004). TF-positive MPs in different types of cancer patients are
known to increase in response to various cellular stresses (Amin
et al, 2008). It is likely that cancer cell-derived MPs contribute to
hypercoagulability in those patients, as various types of cancer
cells are known to secrete TF-positive MPs (Amin et al, 2008). In
these cases, procoagulant activity of TF-positive MPs was
considered to depend on blood-derived fVII. In this study, we
have provided novel evidence that MPs containing active TF-fVIIa
complex are secreted directly from ovarian cancer cells, and that
this phenomenon is enhanced under hypoxia. Given that ovarian
cancer patients have a high incidence of VTE at distant sites from
neoplastic tissue (Tateo et al, 2005; Satoh et al, 2007), cancer cell-
derived TF-fVIIa-positive MPs may have a function in intra-
vascular thrombosis in such patients.
Elevated incidences of VTE have been reported to be associated
with tumour size in gliomas (Marras et al, 2000). Indeed, increase
in tumour volume is associated with progressive development of
hypoxia in many cancer tissues. Thus, it is probable that hypoxic
stresses that are promoted as ovarian cancer grows, especially in
the peritoneal cavity, accentuate the secretion of TF-fVIIa-positive
MPs, leading to the development of VTE. Future investigations
into the relationship between the ectopic expression of fVII in
tumour tissue; plasma concentrations of TF or TF-fVIIa-positive
MPs; and the incidence of VTE in ovarian cancer patients will lead
to a greater understanding of the mechanisms of thrombosis in
cancer patients.
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